Neuroleptic malignant syndrome in Huntington disease
NMS in HD patients is seldom described. This could be due to an underestimation of this condition. There are no available objective NMS diagnostic criteria at present, and the existence of atypical forms of NMS further complicates diagnosis. Advanced disease stage, rigid-akinetic phenotype, abrupt therapy changes, polytherapy, and dehydration are key risk factors, most of which are preventable through awareness and caution in managing medications in the HD population.
Authors
- Paola Zinzi (ORCID: https://orcid.org/0000-0001-5379-4674)
- Anna Rita Bentivoglio (ORCID: https://orcid.org/0000-0002-9663-095X)
- Marcella Solito (ORCID: https://orcid.org/0000-0002-9120-058X)
- Paolo Calabresi (ORCID: https://orcid.org/0000-0003-0326-5509)
- Martina Petracca (ORCID: https://orcid.org/0000-0001-8033-3785)
- Beatrice Ravera
- Antonio Funcis (ORCID: https://orcid.org/0009-0009-6134-5268)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1111/ene.16442
- Citations
- 3
- Primary Topic
- Electroconvulsive Therapy Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16